This study is a multicenter, prospective, open-label, endpoint-blind, randomized controlled study.Patients receiving surgical treatment for SICH were divided into groups using the random machine method. In addition to conventional treatment for spontaneous intracerebral hemorrhage, patients in the group of early initiation of antiplatelet therapy were given conventional dose of aspirin (100mg, qd) antiplatelet therapy starting from the 3rd day after surgery.An independent group of investigators evaluated cardiac, cerebral and peripheral vascular events and bleeding events at four different time points.To evaluate the benefits and safety of early postoperative initiation of antiplatelet therapy in patients with spontaneous intracerebral hemorrhage.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
rate of intracranial hemorrhage
Timeframe: 7 days after surgery
rate of intracranial hemorrhage
Timeframe: 14 days after surgery
rate of intracranial hemorrhage
Timeframe: 30 days after surgery
rate of intracranial hemorrhage
Timeframe: 90 days after surgery
rate of major adverse cardiac/cerebrovascular and peripheral vessel events
Timeframe: 7 days after surgery
rate of major adverse cardiac/cerebrovascular and peripheral vessel events
Timeframe: 14 days after surgery
rate of major adverse cardiac/cerebrovascular and peripheral vessel events
Timeframe: 30 days after surgery
rate of major adverse cardiac/cerebrovascular and peripheral vessel events
Timeframe: 90 days after surgery